# Oric Pharmaceuticals, Inc. (ORIC) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ORIC
## Company Profile
- Ticker: ORIC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 12.93 USD
- Market cap: 788803822.44 USD
- Last updated: 2026-08-05
## Business Overview
### Oncology Resistance Biology
ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments.
### Rinzimetostat
Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is being developed with the androgen-receptor inhibitor darolutamide for metastatic castration-resistant prostate cancer after prior abiraterone treatment.
### Himalayas-1
Himalayas-1 is the planned global Phase 3 registrational trial of rinzimetostat plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer. Dose-optimization results supported selection of 400 mg once daily as the recommended Phase 3 dose.
### Enozertinib
Enozertinib is another clinical-stage ORIC oncology program approaching multiple data updates. The company intends to use these results to determine whether the asset is ready to enter registrational development.
## Why The Stock Is Moving

As of Aug 5, 2026, ORIC closed down 4.01% at $12.93. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of the Phase 3 Himalayas-1 trial expected in the first half of 2026.
- Rinzimetostat program update expected in the second half of 2026.
- Multiple enozertinib clinical updates expected in the second half of 2026 ahead of a potential registrational trial.

## Drug Assets

- rinzimetostat

## Recent News
- 2026-08-03 20:05 EST — [ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operation-3a2b7016) — Source: Oric Pharmaceuticals, Inc.
- 2026-07-20 12:30 EST — [ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-announces-three-presentations-at-the-european-society-for-m-f80acd25) — Source: Oric Pharmaceuticals, Inc.
- 2026-07-14 20:05 EST — [ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc--dcb62dc5) — Source: Oric Pharmaceuticals, Inc.
- 2026-07-02 20:30 EST — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--dc394a6b) — Source: Oric Pharmaceuticals, Inc.
- 2026-05-27 20:05 EST — [ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ORIC/oricr-pharmaceuticals-to-participate-in-upcoming-investor-conferences) — Source: Oric Pharmaceuticals, Inc.